Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0006-2952(79)90696-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial.
Gut
January 2025
Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK
Background: Low-dose amitriptyline, a tricyclic antidepressant (TCA), was superior to placebo for irritable bowel syndrome (IBS) in the AmitripTyline at Low-dose ANd Titrated for Irritable bowel syndrome as Second-line treatment (ATLANTIS) trial.
Objective: To perform post hoc analyses of ATLANTIS for predictors of response to, and tolerability of, a TCA.
Design: ATLANTIS randomised 463 adults with IBS to amitriptyline (232) or placebo (231).
Drug-Induced Myoclonus: A Systematic Review.
Medicina (Kaunas)
January 2025
Neurology Department, Cooper University Hospital, Camden, NJ 08103, USA.
: Myoclonus is already associated with a wide variety of drugs and systemic conditions. As new components are discovered, more drugs are suspected of causing this disabling abnormal involuntary movement. This systematic review aims to assess the medications associated with drug-induced myoclonus (DIM).
View Article and Find Full Text PDFAcid sphingomyelinase downregulation alleviates diabetic myocardial fibrosis in mice.
Mol Cell Biochem
January 2025
Department of Cardiology, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory, Disease, Guangzhou Institute of Cardiovascular Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, Guangdong, China.
Increased activity of acid sphingomyelinase (ASMase) has been linked to diabetes and organ fibrosis. Nevertheless, the precise influence of ASMase on diabetic myocardial fibrosis and the corresponding molecular mechanisms remain elusive. In this study, we aim to elucidate whether ASMase contributes to diabetic myocardial fibrosis through the phosphorylation mediated by MAPK, thereby culminating in the development of diabetic cardiomyopathy (DCM).
View Article and Find Full Text PDFEffect of combination therapy of methylfolate with antidepressants in patients with depressive disorder.
BMC Pharmacol Toxicol
January 2025
Department of Community Medicine, Islamic International Medical College (IIMC), Riphah International University, Rawalpindi, Pakistan.
Objective: To determine the relative effectiveness of combination therapy of antidepressants with low-dose methylfolate versus antidepressant monotherapy in patients with depressive disorder.
Methods: In an open-label clinical trial, forty-four patients with depressive disorder (6A70, 6A71, and 6A72 according to ICD-11) received an evidence-based antidepressant therapy (either escitalopram 10-20 mg, sertraline 50-100 mg, fluoxetine 20-40 mg, duloxetine 30-60 mg, mirtazapine 15-30 mg, venlafaxine 75-150 mg, trazodone 50-100 mg, amitriptyline 25-75 mg, or clomipramine 25-75 mg orally daily for 4 weeks). The experimental group, Group B was additionally given a dose of methylfolate 800 µg daily for four weeks.
An evidence-based update on the diagnosis and management of irritable bowel syndrome.
Expert Rev Gastroenterol Hepatol
January 2025
Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
Introduction: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction affecting 5% of the population. The cardinal symptoms are abdominal pain and altered stool form or frequency.
Areas Covered: Diagnosis and management of IBS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!